The pharmaceutical industry gearing up for a shift coming in May 2026. For design engineers, the transition from USP 88 to the rigorous USP 665 for single-use systems is an urgent call to action, as this mandatory change will redefine material qualification and change control processes. Pharmaceutical engineering teams need to strategize to ensure they meet new regulatory requirements.
Switching From Biocompatibility Testing to In-Depth Chemical Analysis
The pharmaceutical industry is running a qualification sprint toward May 1, 2026, when a new standard for Extractables and Leachables (E&L) for polymeric components takes effect. This change means engineers must discard outdated qualitative assessments and adopt new, more in-depth chemical profiling techniques. As the deadline forces companies to re-evaluate their entire component supply chain, design teams are challenged to align internal testing protocols with the new regulatory expectations within a limited time.
Understanding the Limitations of USP 88 Class VI
For decades, the industry treated USP 88 Class VI as the standard, which required qualitative in-vivo biocompatibility tests using animal models. It simply confirmed if a material caused an acute biological reaction over a short testing window.
Unfortunately, Class VI lacks the chemical-specific data needed to conduct accurate risk assessments. Legacy testing methods like biological reactivity tests often fail to identify the specific chemical compounds that migrate into drug products. Relying on the old models exposes manufacturers to serious compliance risks during final drug product submissions.
Historically, engineers assumed that passing a basic biological reactivity test guaranteed complete safety for downstream processing. Now, biological manufacturing necessitates extended exposure times and highly aggressive solvents. These harsh conditions can easily extract harmful compounds that simple animal models cannot detect.
What Is the Risk-Based Framework of USP 665?
USP 665 introduces a mandatory scientific characterization of materials by establishing a proportional risk-based framework for all polymeric components. Engineers evaluate contact type, contact duration, operating temperatures and specific solvent characteristics to determine exact testing requirements.
The goal is to perform rigorous analytical testing to pinpoint potential extractables (PERLs) and fully map the chemical profiles of all wetted components. Manufacturers then use this precise data to conduct product-specific risk assessments. The USP 1665 framework supplies the rules for evaluating material risks using these chemical profiles and specifies which single-use components require comprehensive testing.
That said, design engineering professionals must immediately familiarize themselves with this detailed chemical profiling methodology. The regulation targets organic compounds migrating from the polymer matrix, and engineers can use this data to predict interactions with sensitive biological drug products.
The Impact on Single-Use Systems
This regulatory mandate affects the daily operations of design engineers worldwide with a scope that expands far beyond basic storage containers or simple tubing lines. USP 665 applies to virtually all plastic components used by biopharmaceutical companies in drug substance and product manufacturing. It covers the exact single-use media storage units, fluid transfer lines, manifolds, filters and sensors featuring polymeric wetted parts.
The standard leaves zero room for uncharacterized plastics anywhere in the fluid path, so design engineers must evaluate each component for exact compliance. Suppliers are also expected to provide comprehensive data packages for every product manufactured. Without this chemical profile, drug manufacturers cannot validate their systems or secure regulatory approvals.
Why Integrity in Manufacturing Is Critical
Drug safety and security are the main reasons why this new mandate is crucial. Unidentified extractables pose serious threats to the drug's efficacy and patient safety. Stray molecules can trigger unintended chemical interactions and degrade active pharmaceutical ingredients inside the bioreactor.
Environmental stressors also drastically amplify these material risks during bioprocessing. High processing temperatures accelerate the migration of harmful extractables from single-use plastics directly into liquid drug products.
Just as proper pharmaceutical storage practices dictate strict temperature controls to maintain drug quality, manufacturing environments require the same vigilance. Under excessive heat, medications undergo chemical reactions. High humidity and moisture exposure cause hydrolysis for specific drugs. Engineers must select materials capable of withstanding extreme processing conditions without shedding toxic compounds, especially as even trace amounts of leached chemicals can ruin multimillion-dollar biological batches.
Building a Plan for Re-qualification and Change Control
Achieving single-use system compliance demands concerted action from all engineering departments. The main challenge is simultaneously auditing current inventory while overhauling standard operating procedures — all before the deadline.
Re-qualifying Existing 2D and 3D Bag Assemblies
Every 2D and 3D bag assembly should have new compliance documentation aligned with USP 665 because companies cannot grandfather in legacy equipment under the previous guidelines. Engineers must actively engage their component suppliers to secure these updated data packages, and this process will demand significant time and resources from both parties.
This transition will, no doubt, require massive scientific validation. If historical data proves insufficient, manufacturers must commission brand-new laboratory testing to generate the required extractables profiles. Independent testing laboratories currently face massive backlogs as the industry rushes to secure this critical data.
Redefining Change Control Protocols
The updated standard absolutely requires stricter change control protocols across all manufacturing sites. This means engineers can no longer execute simple, identical component swaps based solely on dimensional specifications.
Every minor material adjustment should undergo intense chemical scrutiny. If a supplier alters a polymer formulation, modifies a specific manufacturing process or changes a sub-tier vendor, the design engineer must initiate a brand-new risk assessment.
Engineering managers must rewrite standard operating procedures to mandate full chemical profiling for any supply chain alteration. They must completely shift away from identical component swaps and embrace strict data-driven qualification for every single change.
Leveraging Supplier Partnerships for a Seamless Transition
Engineers cannot conquer this qualification sprint alone. Success depends largely on forging collaborative relationships with single-use component manufacturers. All parties must share technical data openly to guarantee compliance.
What to Request from Component Suppliers
Design engineering professionals must immediately establish strict new expectations for their vendors. A basic certificate of compliance no longer satisfies regulatory demands. Engineers should require comprehensive analytical testing data up front before specifying any new component.
Suppliers must also disclose the exact methods of extraction, detail the specific analytical techniques used and provide an exhaustive list of identified compounds. Transparency regarding material sourcing and secondary processing agents is mandatory for vendor qualification.
Integrating Supplier Data into Risk Assessments
Engineers systematically extract the supplier data to execute internal safety evaluations. They plug these precise chemical profiles into toxicological models to verify overall patient safety. This data integration will directly support critical regulatory filings.
Teams must initiate open communication channels with component suppliers immediately. Proactive dialogue prevents costly delays during the final validation phases of facility design. Engineers who master this data integration process drastically reduce time-to-market for new drug products.
Charting the Path Forward With USP 665
The move to USP 665 highlights the pharmaceutical industry's commitment to deeper scientific understanding and absolute patient safety. For engineers, this mandate presents an exceptional opportunity to lead the charge in building more resilient and rigorously validated manufacturing processes. Design teams must immediately assess their readiness and determine the resources needed to secure flawless execution before the deadline.
